# Deutenzalutamide

Source: https://onco.cc/drugs/deutenzalutamide/  
OnCo record `deutenzalutamide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Deutenzalutamide is a hormone-blocking capsule from Hinova Pharmaceuticals, a modified form of enzalutamide, approved in China in 2025 for prostate cancer that has spread and stopped responding to hormone therapy.

## Summary

Deutenzalutamide (HC-1119, HC1119, 海纳安) is a small molecule (oral soft capsule), deuterated androgen receptor antagonist from Hinova Pharmaceuticals. A deuterated form of enzalutamide, a second-generation androgen receptor antagonist; in preclinical models it had a lower metabolic rate, higher plasma exposure and lower brain exposure than enzalutamide at equivalent doses. Its furthest stage is approval, for metastatic castration-resistant prostate cancer. ClinicalTrials.gov registers it in 5 studies linked below. Approved by China's NMPA on 29 May 2025 for metastatic castration-resistant prostate cancer (Hinova English pipeline page); added to China's national reimbursement drug list in December 2025 (Hinova Chinese pipeline page). No approval elsewhere in sources read; the global phase 3 vs enzalutamide (NCT03850795, Hinova USA) is terminated.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-11-03
- Also known as: HC-1119; HC1119; 海纳安; 氘恩扎鲁胺软胶囊
- Tags: pipeline; ctgov-ingest
- Code: HC-1119
- Modality: Small molecule (oral soft capsule), deuterated androgen receptor antagonist
- Mechanism: A deuterated form of enzalutamide, a second-generation androgen receptor antagonist; in preclinical models it had a lower metabolic rate, higher plasma exposure and lower brain exposure than enzalutamide at equivalent doses.
- Approvals: China 2025: Metastatic castration-resistant prostate cancer

## Sources

- Hinova Pharmaceuticals: hinovapharma.com: https://www.hinovapharma.com/en/chanpinxianguan.html
- Hinova Pharmaceuticals: hinovapharma.com: https://www.hinovapharma.com/en/chanpinxianguan.html
- Hinova Pharmaceuticals: hinovapharma.com: https://www.hinovapharma.com/chanpinxianguan.html
- ClinicalTrials.gov: trials of HC-1119: https://clinicaltrials.gov/search?intr=HC-1119

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- companies: [Hinova Pharmaceuticals](https://onco.cc/companies/hinova-pharmaceuticals/)
- trials: [A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch](https://onco.cc/trials/nct03778047/), [A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics](https://onco.cc/trials/nct03776968/), [A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.](https://onco.cc/trials/nct03774056/), [A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).](https://onco.cc/trials/nct03851640/), [HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)](https://onco.cc/trials/nct03850795/)

---
JSON: https://onco.cc/api/v1/entities/deutenzalutamide.json